Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Structure, Transmission, Diagnostic Symptoms, Host and Entry Mechanism of COVID-19: A Review

Author(s): Prashant Swapnil, Mukesh Meena*, Tansukh Barupal, Yashwant Sompura and Deepa Hada

Volume 2, Issue 5, 2021

Published on: 16 November, 2020

Article ID: e300421188050 Pages: 9

DOI: 10.2174/2666796701999201116213826

Price: $65

Abstract

In Wuhan, China, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been reported and caused coronavirus disease 19 (COVID-19). The coronavirus infection is pathogenic and highly transmittable and spread quickly around the world by the human to human contact. Through genomic analysis, it has been revealed that the primary reservoir of SARS-CoV-2 is bats due to having severe acute respiratory syndrome-like (SARS-like) viruses phylogenetically. The viral infection is rapidly transmitted by the human to human contact, but the intermediate source of their origin and transfer is not known. To date, any clinically approved vaccine or antiviral drug has not been prepared against COVID-19. However, researchers and scientists have evaluated some broad-spectrum antiviral drugs against COVID-19 through clinical trials and they have found satisfactory clinical recovery. This review summarizes the comparative analysis of the emergence and pathogenicity of COVID-19, severe acute respiratory syndrome coronavirus (SARS-CoV), and Middle East respiratory syndrome coronavirus (MERS-CoV). This review is also focused on the development of effective vaccines or antidrug and also provides details related to an approach to practice therapeutic combinations to fight against this viral outbreak.

Keywords: COVID-19, SARS-CoV-2, glycoprotein, infection, symptoms, prevention.

Graphical Abstract

[1]
Gorbalenya AE, Baker SC, Baric RS, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5(4): 536-44.
[http://dx.doi.org/10.1038/s41564-020-0695-z] [PMID: 32123347]
[2]
Wang N, Shi X, Jiang L, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 2013; 23(8): 986-93.
[http://dx.doi.org/10.1038/cr.2013.92] [PMID: 23835475]
[3]
Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17(3): 181-92.
[http://dx.doi.org/10.1038/s41579-018-0118-9] [PMID: 30531947]
[4]
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020; 55(3)105924
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105924] [PMID: 32081636]
[5]
World Health Organization. Laboratory testing for coronavirus disease 2019. (COVID-19) in suspected human cases: interim guidance. Available from: https://apps.who.int/iris/handle/10665/331329
[6]
Reuters Staff. False claim: COVID-19 stands for certification of vaccination identification by artificial intelligence. Available from: https://www.reuters.com/article/uk-factcheck-covid-name-abbrevi-ation/false-claim-covid-19-stands-for-certification-of-vaccination-identification-by-artificial-intelligence-idUSKCN2262AS
[7]
ICTV. ICTV Executive committee 2020 - 2023. Available from: https://talk.ictvonline.org/information/w/news/1300/page
[8]
Chan JFW, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395(10223): 514-23.
[http://dx.doi.org/10.1016/S0140-6736(20)30154-9] [PMID: 31986261]
[9]
Dhand R, Li J. Coughs and sneezes: Their role in transmission of respiratory viral infections, including SARS-CoV-2. Am J Respir Crit Care Med 2020; 202(5): 651-9.
[http://dx.doi.org/10.1164/rccm.202004-1263PP] [PMID: 32543913]
[10]
Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet 2020; 395(10242): 1973-87.
[http://dx.doi.org/10.1016/S0140-6736(20)31142-9] [PMID: 32497510]
[11]
Park SY, Kim YM, Yi S, et al. Coronavirus disease outbreak in call center, South Korea. Emerg Infect Dis 2020; 26(8): 1666-70.
[http://dx.doi.org/10.3201/eid2608.201274] [PMID: 32324530]
[12]
Byambasuren O, Cardona M, Bell K, Clark J, McLaws M, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis MedRxiv 2020051020097543
[http://dx.doi.org/10.1101/2020.05.10.20097543]
[13]
Tabata S, Imai K, Kawano S, et al. Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis. Lancet Infect Dis 2020; 20(9): 1043-50.
[http://dx.doi.org/10.1016/S1473-3099(20)30482-5] [PMID: 32539988]
[14]
Bourouiba L. Turbulent gas clouds and respiratory pathogen emissions: potential implications for reducing transmission of COVID-19. JAMA 2020; 323(18): 1837-8.
[http://dx.doi.org/10.1001/jama.2020.4756] [PMID: 32215590]
[15]
Lewis D. Is the coronavirus airborne? Experts can’t agree. Nature 2020; 580(7802): 175.
[16]
Dashraath P, Wong JLJ, Lim MXK, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol 2020; 222(6): 521-31.
[http://dx.doi.org/10.1016/j.ajog.2020.03.021] [PMID: 32217113]
[17]
Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020; 395(10226): 809-15.
[http://dx.doi.org/10.1016/S0140-6736(20)30360-3] [PMID: 32151335]
[18]
Zeng L, Xia S, Yuan W, et al. Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China. JAMA Pediatr 2020; 174(7): 722-5.
[http://dx.doi.org/10.1001/jamapediatrics.2020.0878] [PMID: 32215598]
[19]
van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020; 382(16): 1564-7.
[http://dx.doi.org/10.1056/NEJMc2004973] [PMID: 32182409]
[20]
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020; 324(8): 782-93.
[http://dx.doi.org/10.1001/jama.2020.12839] [PMID: 32648899]
[21]
McIntosh K, Hirsch MS, Bloom A. Coronavirus disease 2019. (COVID-19). Available from: https://www.cmim.org/PDF_ covid/Coronavirus_disease2019_COVID-19_UpToDate2.pdf
[22]
Center for disease control and prevention. People with certain medical conditions. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
[23]
Martinez RM. Clinical samples for SARS-CoV-2 detection: review of the early literature. Clin Microbiol Newsl 2020; 42(15): 121-7.
[http://dx.doi.org/10.1016/j.clinmicnews.2020.07.001] [PMID: 32834295]
[24]
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol 2020; 95(7): 834-47.
[http://dx.doi.org/10.1002/ajh.25829] [PMID: 32282949]
[25]
Jain N, Choudhury A, Sharma J, Kumar V, De D, Tiwari R. A review of novel coronavirus infection (Coronavirus Disease-19). Glob J Transfus Med 2020; 5(1): 22.
[http://dx.doi.org/10.4103/GJTM.GJTM_24_20]
[26]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507-13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[27]
Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020; 368: m606.
[http://dx.doi.org/10.1136/bmj.m606] [PMID: 32075786]
[28]
Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis. Diagnostics (Basel) 2020; 10(5): 319.
[http://dx.doi.org/10.3390/diagnostics10050319] [PMID: 32438677]
[29]
Hou H, Wang T, Zhang B, et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunology 2020; 9(5)e01136
[http://dx.doi.org/10.1002/cti2.1136.]
[30]
Geng S, Mei Q, Zhu C, et al. High flow nasal cannula is a good treatment option for COVID-19. Heart Lung: J Cardiopulmonary Acute Care 2020; 49(5): 444-5.
[http://dx.doi.org/10.1016/j.hrtlng.2020.03.018.]
[31]
de Sequera Ortiz P, Gili BQ, de la Fuente GDA, Heras MM, Lazo MS, Pino MDDP. Protocol against coronavirus diseases in patients on renal replacement therapy: Dialysis and kidney transplant. Nefrologia 2020; 40: 253-7.
[http://dx.doi.org/10.1016/j.nefroe.2020.03.010.]
[32]
Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 2020; 87(4): 281-6.
[http://dx.doi.org/10.1007/s12098-020-03263-6] [PMID: 32166607]
[33]
World Health Organization. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19 Available from: https://www. who. int/news-room/detail/04-07-2020-who-discontinueshydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-forcovid-19
[34]
Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 2020; 92(9): 1518-24.
[http://dx.doi.org/10.1002/jmv.25727] [PMID: 32104917]
[35]
Chen ZM, Fu JF, Shu Q, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr 2020; 16(3): 240-6.
[http://dx.doi.org/10.1007/s12519-020-00345-5] [PMID: 32026148]
[36]
World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus [nCoV] infection is suspected Available from: https://www.who.int/publications-detail/clinical-management
[37]
Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382(10): 929-36.
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID: 32004427]
[38]
Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol 2020; 92(5): 479-90.
[http://dx.doi.org/10.1002/jmv.25707] [PMID: 32052466]
[39]
Hamre D, Procknow JJ. A new virus isolated from the human respiratory tract. Proc Soc Exp Biol Med 1966; 121(1): 190-3.
[http://dx.doi.org/10.3181/00379727-121-30734] [PMID: 4285768]
[40]
McIntosh K, Dees JH, Becker WB, Kapikian AZ, Chanock RM. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci USA 1967; 57(4): 933-40.
[http://dx.doi.org/10.1073/pnas.57.4.933] [PMID: 5231356]
[41]
Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348(20): 1967-76.
[http://dx.doi.org/10.1056/NEJMoa030747] [PMID: 12690091]
[42]
Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300(5624): 1394-9.
[http://dx.doi.org/10.1126/science.1085952] [PMID: 12730500]
[43]
World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Available from: http://www.who.int/csr/sars/country/table2004_04_ 21/en/
[44]
van der Hoek L, Pyrc K, Jebbink MF, et al. Identification of a new human coronavirus. Nat Med 2004; 10(4): 368-73.
[http://dx.doi.org/10.1038/nm1024] [PMID: 15034574]
[45]
Woo PC, Lau SK, Chu CM, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 2005; 79(2): 884-95.
[http://dx.doi.org/10.1128/JVI.79.2.884-895.2005] [PMID: 15613317]
[46]
Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367(19): 1814-20.
[http://dx.doi.org/10.1056/NEJMoa1211721] [PMID: 23075143]
[47]
Korea Centers for Disease Control and Prevention. Middle east respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015. Osong Public Health Res Perspect 2015; 6(4): 269-78.
[http://dx.doi.org/10.1016/j.phrp.2015.08.006] [PMID: 26473095]
[48]
Barupal T, Tak PK, Meena M. COVID-19: Morphology, characteristics, symptoms, prevention, clinical diagnosis and current scenario. Coronaviruses 2020; 1: 82-9.
[http://dx.doi.org/10.2174/2666796701999200617161348]
[49]
Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020; 24: 91-8.
[http://dx.doi.org/10.1016/j.jare.2020.03.005] [PMID: 32257431]
[50]
Sethna PB, Hofmann MA, Brian DA. Minus-strand copies of replicating coronavirus mRNAs contain antileaders. J Virol 1991; 65(1): 320-5.
[http://dx.doi.org/10.1128/JVI.65.1.320-325.1991] [PMID: 1985203]
[51]
Brown CG, Nixon KS, Senanayake SD, Brian DA. An RNA stem-loop within the bovine coronavirus nsp1 coding region is a cis-acting element in defective interfering RNA replication. J Virol 2007; 81(14): 7716-24.
[http://dx.doi.org/10.1128/JVI.00549-07] [PMID: 17475638]
[52]
Guan BJ, Wu HY, Brian DA. An optimal cis-replication stem-loop IV in the 5′ untranslated region of the mouse coronavirus genome extends 16 nucleotides into open reading frame 1. J Virol 2011; 85(11): 5593-605.
[http://dx.doi.org/10.1128/JVI.00263-11] [PMID: 21430057]
[53]
Liu P, Li L, Keane SC, Yang D, Leibowitz JL, Giedroc DP. Mouse hepatitis virus stem-loop 2 adopts a uYNMG(U)a-like tetraloop structure that is highly functionally tolerant of base substitutions. J Virol 2009; 83(23): 12084-93.
[http://dx.doi.org/10.1128/JVI.00915-09] [PMID: 19759148]
[54]
Raman S, Bouma P, Williams GD, Brian DA. Stem-loop III in the 5′ untranslated region is a cis-acting element in bovine coronavirus defective interfering RNA replication. J Virol 2003; 77(12): 6720-30.
[http://dx.doi.org/10.1128/JVI.77.12.6720-6730.2003] [PMID: 12767992]
[55]
Liu Q, Johnson RF, Leibowitz JL. Secondary structural elements within the 3′ untranslated region of mouse hepatitis virus strain JHM genomic RNA. J Virol 2001; 75(24): 12105-13.
[http://dx.doi.org/10.1128/JVI.75.24.12105-12113.2001] [PMID: 11711601]
[56]
Goebel SJ, Miller TB, Bennett CJ, Bernard KA, Masters PS. A hypervariable region within the 3′ cis-acting element of the murine coronavirus genome is nonessential for RNA synthesis but affects pathogenesis. J Virol 2007; 81(3): 1274-87.
[http://dx.doi.org/10.1128/JVI.00803-06] [PMID: 17093194]
[57]
Williams GD, Chang RY, Brian DA. A phylogenetically conserved hairpin-type 3′ untranslated region pseudoknot functions in coronavirus RNA replication. J Virol 1999; 73(10): 8349-55.
[http://dx.doi.org/10.1128/JVI.73.10.8349-8355.1999] [PMID: 10482585]
[58]
Hsue B, Masters PS. A bulged stem-loop structure in the 3′ untranslated region of the genome of the coronavirus mouse hepatitis virus is essential for replication. J Virol 1997; 71(10): 7567-78.
[http://dx.doi.org/10.1128/JVI.71.10.7567-7578.1997] [PMID: 9311837]
[59]
Hsue B, Hartshorne T, Masters PS. Characterization of an essential RNA secondary structure in the 3′ untranslated region of the murine coronavirus genome. J Virol 2000; 74(15): 6911-21.
[http://dx.doi.org/10.1128/JVI.74.15.6911-6921.2000] [PMID: 10888630]
[60]
Bergmann CC, Lane TE, Stohlman SA. Coronavirus infection of the central nervous system: host-virus stand-off. Nat Rev Microbiol 2006; 4(2): 121-32.
[http://dx.doi.org/10.1038/nrmicro1343] [PMID: 16415928]
[61]
Sawicki SG, Sawicki DL, Siddell SG. A contemporary view of coronavirus transcription. J Virol 2007; 81(1): 20-9.
[http://dx.doi.org/10.1128/JVI.01358-06] [PMID: 16928755]
[62]
U.S. food and drug.. Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19 treatment. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment
[63]
Cao B, Wang Y, Wen D, et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382(19): 1787-99.
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]
[64]
Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother 2020; 64(5): e00399-20.
[http://dx.doi.org/10.1128/AAC.00399-20] [PMID: 32152082]
[65]
Hoehl S, Rabenau H, Berger A, et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. N Engl J Med 2020; 382(13): 1278-80.
[http://dx.doi.org/10.1056/NEJMc2001899] [PMID: 32069388]
[66]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[67]
Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun 2004; 318(3): 719-25.
[http://dx.doi.org/10.1016/j.bbrc.2004.04.083] [PMID: 15144898]
[68]
Reuters. Fujifilm to start phase II clinical trial of Avigan for COVID-19 patients in US Available from: https://www.reuters. com/article/us-health-coronavirus-fujifilmavigan/fujifilm-to-start-phase-ii-clinical-trial-of-avigan-for-covid-19-patients-in-u-s-idUSKCN21R0KF
[69]
First Wave Bio. FirstWave bio to initiate phase 2a/2b study of FW1022, a proprietary form of Niclosamide, to treat COVID-19. Available from: https://www.biospace.com/article/releases/firstwave-bio-to-initiate-phase-2a-2b-study-of-fw-1022-a-proprietary-form-of-niclosamide-to-treat-covid-19/
[70]
AP News. IM Immuno tech's drug ampligen to be tested by Japan's national institute of infectious diseases as a potential treatment for the new SARS coronavirus (SARS-CoV-2) responsible for the new human infectious disease COVID-19 AIM ImmunoTech 2020. Available from: https://apnews.com/press-release/pr-accesswire/b109503178f34684ce3a0007b34bc7e0
[71]
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020; 178104787
[http://dx.doi.org/10.1016/j.antiviral.2020.104787] [PMID: 32251768]
[72]
Sharma S, Swapnil P, Meena MA. Novel 2019 severe acute respiratory syndrome coronavirus 2 (COVID-19) as global pandemic. Cell Cellular Life Sci J 2020; 5(2)000154
[http://dx.doi.org/10.23880/cclsj-16000154]
[73]
Meena M, Swapnil P. A review of contagious coronavirus (SARSCov-2) their clinical features, diagnosis, preventions and treatment. J Hum Virol Retrovirolog 2020; 8(4): 99-105.
[http://dx.doi.org/10.15406/jhvrv.2020.08.00227]

Rights & Permissions Print Cite
Article Metrics
24
1
© 2024 Bentham Science Publishers | Privacy Policy